Anticancer effect and immunologic response to xenogeneic embryonic proteins in mice bearing ehrlich solid carcinoma by Symchych, T.V. et al.
42 Experimental Oncology 39, 42–48, 2017 (March)
ANTICANCER EFFECT AND IMMUNOLOGIC RESPONSE 
TO XENOGENEIC EMBRYONIC PROTEINS IN MICE BEARING 
EHRLICH SOLID CARCINOMA
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Aim: To investigate anticancer and immunologic effects of chicken embryonic proteins (CEP) in mice bearing Ehrlich solid carcinoma. 
Materials and Methods: The study was carried out on male Balb/c mice bearing Ehrlich solid carcinoma. The immunizations were 
performed after the tumor transplantation. The immune status was assessed on days 7, 14, 21 and 28 after the tumor challenge. 
Cytotoxic activity (CAT) of macrophages (Mph), natural killer cells (NK), cytotoxic T-lymphocytes (CTL) and blood serum, as well 
as the influence of the blood serum on immune cells activity was checked in MTT-assay; Mph’s cytochemical activity was tested 
in NBT-assay; Ehrlich antigen-specific or CEP-specific antibodies were detected in ELISA-assay; medium size circulating immune 
complexes (CIC) were detected in reaction of 4.5% polyethylene glycol precipitation. Results: The immunization resulted in tumor 
growth suppression and significant 25.64% prolongation of the survival time. In both control and immunized mice with transplanted 
tumors antibodies specific to Ehrlich carcinoma antigens and to CEP were detected, but antibody response was more balanced in the 
treatment group. In the treatment group both cytochemical and CAT of Mph was moderately activated and well preserved until late 
stages of tumor development; CAT of NK and CTL remained in the range of the intact mice until day 28 after the tumor transplanta-
tion. The immunized mice were well protected from accumulation of CIC and suppressive activity of autologous blood serum. Conclu-
sion: Collectively, our data indicate that CEP can elicit immunomodulating and immunoprotecting effects sufficient to provide tumor 
growth inhibition. The further elaboration of a xenogeneic anticancer vaccine based on CEP is warranted.
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Anticancer xenogeneic vaccine elaboration started 
after 1996 when Naftzger and coauthors showed that 
human gp75 could elicit antibodies (Abs) response 
to mouse gp75 in mice [1]. So, it was shown that 
xenogeneic homologous proteins can break immune 
tolerance to autologous cancer antigens (Ag), and 
stimulated xenogeneic anticancer vaccines develop­
ment [2]. Some of these vaccines are already undergo­
ing clinical trials [3].
As a source of xenogeneic Ag, chicken embryos are 
often utilized. Indeed, some proteins or genes of chi­
cken origin when used as a xenogeneic vaccine showed 
an anticancer effect in case of different murine tumors 
models (Lewis lung carcinoma, murine H22 hepatoma, 
melanoma B­16, Meth A fibrosarcoma, CT26 colon 
adenocarcinoma) [4–7] and in an experimental canine 
transmissible venereal tumor model [8]. At R.E. Ka­
vetsky Institute of Experimental Pathology, Oncology 
and Radiobiology of the NAS of Ukraine (IEPOR), the 
work is proceeding on elaboration of a xenogeneic 
vaccine based on chicken embryonic proteins (CEP). 
In previous experiments, its anticancer and antimeta­
static effects were demonstrated on Lewis lung car­
cinoma model [9]. By the Guideline on the preclinical 
evaluation of medical products [10], the anticancer 
effect of preparation should be stu died in 2–3 different 
tumor models. Consequently, the purpose of this work 
was to investigate anticancer and immunologic effects 
of CEP in mice bearing solid Ehrlich carcinoma (EC).
MATERIALS AND METHODS
The study has been carried out on 60 male 
Balb/c mice 2–2.5 month old weighting 20–21 g, bred 
at the vivarium of IEPOR (Kyiv, Ukraine). The use and 
care of experimental animals have been performed 
in accordance with standard international rules on bio­
logic ethics and was approved by Institutional Animal 
Care and Use Committee [11].
To establish tumors, 4•105 cells/mouse of EC cells 
were injected i.m. into the right hind leg.
Tumor bearing mice (n = 26) were immunized 
on days 2, 5, and 8 after tumor cells transplanta­
tion. The immunization was performed s.c. with 
0.3 ml of CEP solution per mouse (protein concentra­
tion 0.3 mg/ml). Nonimmunized tumor bearing mice 
(n = 26) were referred as nonimmunized control.
The CEP was prepared by extraction of 7­days 
chicken embryos with 0.9% NaCl solution, containing 
0.1% EDTA as described in [12]. The resulting super­
natant was collected and frozen at −20 °C.
Tumor dimensions were measured with calipers, and 
tumor volumes were calculated according to the formula:
tumor volume = 4/3π • width2 • length • 0,5.
Index of Tumor Growth Inhibition (ITGI) was calcu­
lated according to the formula:
ITGI = ((Vcontrol mice — Vimmunized mice) / Vcontrol mice) × 100%
where Vcontrol mice and Vimmunized mice stand for mean 
tumor volume in the control and immunized mice, 
respectively.
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Index of Life Span Prolongation (ILSP) was calcu­
lated as following:
ILSP = ((survival timeimmunized mice — survival  
timecontrol mice) / survival timecontrol mice) • 100%,
where survival timeimmunized mice and survival 
timecontrol mice stand for mean survival time (days) in the 
immunized and control groups, respectively.
Immunological examination was performed on days 
7, 14, 21 and 28 after the tumor transplantation. Data 
on the immunized mice (n = 12) were compared with 
nonimmunized tumor­bearing control (n = 12) and 
intact mice (n = 8) of the same strain, sex and age 
(is referred as the intact control).
Cytotoxic activity (CTA) of blood serum (BS), 
spleen lymphocytes and peritoneal macrophages 
(Mph) was determined by МТТ­assay [13, 14]. 
K­562 cells were used as target cells for the examination 
of natural killer cell (NK) CAT, while EC cells were used 
as targets for cytotoxic T­lymphocytes (CTL), Mph and 
BS. In brief, target cells (2•104 cell/well) and immune 
cells (1•105 lymphocytes/well or 4•105 Mph/well) were 
placed in a flat­bottom 96­well plate and incubated for 
18 h in a humidity atmosphere with 5% СО2 at 37 °С. Af­
ter that, 0.01 ml of МТТ solution/well (5 mg/ml, Sigma) 
was added, and incubation continued for 2 h. Then 
the plates were centrifuged (1500 g for 15 min) and 
washed twice with 0.9% NaCl solution. After all, 
0.12 ml of 2 M КОН and 0.14 ml of DMSO (50% solu­
tion) were added into the each well. Optical density was 
measured at λ = 545 nm vs λ = 630 nm with a micro 
ELISA reader (StatFax­2100, USA). Each sample was 
measured in triplicate.
Cytotoxic Activity Index (CTAI, %) was calculated 
by the formula:
CTAI = [1 — (ODic+tc — ODic)/(ODtc — ODblank)] • 100%,
where ODic — optical density of wells in which only 
immune cells were incubated; ODtc — optical density 
of wells in which only target cells were incubated; 
ODic+tc — optical density of wells in which tumor and im­
mune cells where incubated; ODblank — optical density 
of wells with the culture medium only.
In order to determine BS effect on immune cells’ 
CAT, 0.01 ml of autologous BS was added to “target + 
immune cells” containing wells. All the other steps were 
the same as is described above.
Cytochemical activity of Mph (spontaneous 
and induced with pyrogenal) was studied in NBT­ 
assay [15]. In brief, Mph (1•106 cell/ml, 0.2 ml/well) 
were incubated with 0.02 ml/well 0.2% NBT solu­
tion (Sigma, USA). To induce cytochemical activity, 
0.013 ml/well of pyrogenal (100 mkg/ml, Medhamal, 
RF) was used. After incubation (1 h, 5% СО2, 37 °С), 
the plates were washed twice with 0.9% NaCl so­
lution. 2 M KOH solution (0.06 ml/well) and 50% 
DMSO solution (0.07ml/well) were used to dissolve 
diformazan granu les. Optical density was measured 
at λ = 630 nm with the use of micro ELISA reader (Stat­
Fax­2100, USA). Each sample was measured in tripli­
cate. The results are presented as optical units (OU).
Activation Index (AI) was calculated as following:
AI = OU(induced test) / OU(spontaneous test), 
where OU(induced test) and OU(spontaneous test) stand for opti­
cal units of wells with pyrogenal treated and untreated 
Mph respectively.
Circulating immune complexes (CIC) in BS of the 
mice were detected in reaction of 4.5% polyethylene 
glycol (PEG) precipitation [16]. Optical density was 
measured at λ = 450 nm with the use of micro ELISA 
reader (StatFax­2100, USA), and the data are pre­
sented as reference unit: 
RU(CIC) = (OUPEG well — OUcontrol well) • 100, 
where OUcontrol well and OUPEG well stand for, respec­
tively, optical density of control (BS + BBS buffer) and 
test (BS +4.5% PEG in BBS buffer) wells.
CEP- or EC-Ag-specific IgG have been detected 
in an enzyme­linked immunosorbent assay (ELISA) 
as described earlier [17]. Briefly, the 0.1 ml of CEP 
or EC­Ag solution (0.3 mg/ml) were incubated for 
24 h at 4 °C on 96­cells microtiter plates (Dynatech, 
Sweden). Nonspecific binding was blocked with 3% 
BSA for 1 h at 37 °C. Sera were added at dilution 1:20. 
Bound Abs were revealed using goat antimouse IgG per­
oxidase conjugate (Sigma, USA) and o­phenyldiamine/
H2O2 substrates. Reaction was stopped by addition 
of 0.05 ml/well 1 mole/liter H2SO4 solution. Plates were 
read at 492 nm in MicroELISA (StatFax­2100, USA) plate 
reader. The BS of naïve mice of the same strain, age 
and sex was used as the negative control. The results 
are presented as refe rence unit [18]: 
RU(ELISA) = ODexperiment/ODintact control, 
where ODexperiment stands for optical density of cells 
with BS of experimental tumor­bearing mice, ODintact 
control stands for optical density of cells with naïve mice 
serum. The RU(ELISA) value exceeded 2 was taken as in­
dication of Ab­positive serum.
In some cases, Modulation Index (MI) was calcu­
lated for better illustration of the differences between 
the control and experimental groups:
MI = [CTAIexperiment — CTAIcontrol/CTAIcontrol] • 100%,
where CTAIexperiment — index CTA for the group of ex­
perimental tumor­bearing animals; CTAIcontrol — index 
CTA for the group of intact mice of the same strain, 
age and sex.
The statistical analysis was made using Student 
t­test. The difference was considered significant 
at p < 0.05; 0.05 < p < 0.1 was considered to repre­
sent a tendency. Correlation analysis was performed 
using Pearson correlation coefficient adjusted to the 
sample size.
RESULTS
All the mice of the control and treatment groups 
developed EC tumor on day 5–7 after the tumor cell 
transplantation (Table 1).
Table 1. Latent period of tumor development and mean survival time 
in mice bearing Ehrlich solid carcinoma
Group Latent period of tumor development, days
Mean survival 
time, days
Median survi-
val time, days
Nonimmunized (n =14) 5.5 ± 0.34 43.77 ± 2.35 44
CEP immunized (n=14) 6.36 ± 0.78 58.86 ± 4.09* 55
Note: *p < 0.05 compared to the control nonimmunized group.
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Starting from day 13 after the tumor transplantation, 
significant difference (p < 0.05) in tumor volume of the 
control and immunized animals become evident (Fig. 1). 
To illustrate, on days 13 and 16 after the tumor challenge 
ITGI reached 50.57 and 50.74%, respectively. Since day 
20, ITGI started to gradually decline (46.11 and 43.27% 
on days 20 and 23, respectively), but remained higher 
than 25% until the control mice began to die. Due to the 
tumor growth inhibition, the mean survival time of the 
immunized mice was 25.64% longer (p < 0.05) than 
that of the control mice (see Table 1).
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Fig. 1. Tumor growth kinetics in mice bearing Ehrlich solid car­
cinoma (CEP immunized and nonimmunized ones)
So, mice immunized with CEP showed tumor 
growth inhibition and life time prolongation. To ad­
dress the issue of immune effects of CEP immunization 
we carried out an immunological examination of the 
treated and control mice. The mice were challenged 
with EC; on days 2, 5, and 8 after the tumor cells injec­
tion, the mice of the treatment group were immunized 
with CEP. The immunological examination of the ani­
mals was performed on days 7, 14, 21 and 28 after the 
tumor transplantation.
In the group of control tumor bearing mice, spon­
taneous cytochemical activity of Mph was almost the 
same as in the group of intact mice, except on day 
28 of the experiment when it decreased and was sig­
nificantly lower than that in the intact control group 
(Table 2). Although induced cytochemical activity 
of Mph in the control group was suppressed during 
almost entire time of investigation (on days 7 and 
28 p < 0.05 compared to the intact control).
Table 2. Mph cytochemical activity in mice bearing Ehrlich solid carcino-
ma (CEP immunized, nonimmunized, and intact ones)
Group
Day of  
tumor 
growth
Cytochemical activity, OU Activation in-
dex, %Spontaneous
Induced with 
pirogenal
Intact con-
trol (n = 8)
– 0.675 ± 0.045 0.681 ± 0.043 1.008 ± 0.005
Nonimmu-
nized  
(n = 12)
7 0.823 ± 0.075 0.795 ± 0.082 0.966 ± 0.0121
14 0.683 ± 0.018 0.708 ± 0.018 1.037 ± 0.049
21 0.718 ± 0.047 0.710 ± 0.057 0.987 ± 0.020
28 0.616 ± 0.0065 0.580 ± 0.0121*,3,5 0.942 ± 0.0201
CEP immu-
nized  
(n = 12)
7 0.814 ± 0.0221 0.820 ± 0.0361* 1.007 ± 0.017
14 0.660 ± 0.0284 0.684 ± 0.0234 1.038 ± 0.046
21 0.643 ± 0.0234 0.647 ± 0.0474 1.006 ± 0.033
28 0.661 ± 0.0354 0.631 ± 0.0134 0.955 ± 0.0211*
Note: 1p < 0.05 compared to intact control; 1*0.05 < р < 0.1 compared to intact 
control; 2p < 0.05 compared to tumor-bearing control; 3р < 0.05 compared 
to CEP; 4р < 0.05 compared to data obtained on day 7 in the same group; 
5р < 0.05 compared to all the previous days of investigation in the same group.
Mph cytochemical activity of the immunized mice 
showed a different pattern. The highest activity was 
documented on day 7 (p < 0.05 compared to the in­
tact control); thereafter it has slightly decreased but 
never has fallen below the normal range. Induced cy­
tochemical activity in this group remained unchanged 
until day 28 of experiment, when a slight decrease 
was documented (p < 0.07 compared to the intact 
control). In other words, in the treated group of mice, 
contrary to the control group, cytochemical activity 
of Mph was well preserved until the late stages of the 
tumor development.
The difference between Mph CAT in the two 
groups was even more evident (Table 3). For in­
stance, CAT of Mph in the control group was lower 
than that in the intact control group (p < 0.05 on days 
14 and 28). Autologous BS, when added to Mph and 
target cells, was not able to change the pattern, but 
weakened it even more (especially on days 21 and 
28 of tumor growth). To illustrate, BS added to Mph 
and target cells on day 21 led to sharp decrease 
of 37.62% in Mph CAT (compared to Mph CAT without 
BS). On 28 day after the tumor transplantation, ad­
dition of autologous BS totally abrogated Mph CAT 
in 2 out of 3 mice. The last mouse’s CATI was very 
low and made up only 2.58%.
Contrary to the control tumor­bearing group, Mph 
CAT in the treatment group was slightly increased over 
the entire experiment (p < 0.05 on day 7 compared 
to the intact control, on days 14 and 28 compared 
to the tumor­bearing control). Autologous BS added 
to Mph did not change its CAT significantly, except 
day 28, when it caused evident decrease of Mph CTA 
(p < 0.05 compared to the intact control and all the pre­
vious time points). However, it remained by 3.97 times 
higher than that in the control group.
Table 3. CAT of Mph in mice bearing Ehrlich solid carcinoma (CEP immu-
nized and nonimmunized) and intact animals
Group CAT  index, %
Day of tumor growth
7 14 21 28
Intact con-
trol (n = 8)
Mph 23.04 ± 1.29
Mph + BS 22.17 ± 0.71
Nonimmu-
nized  
(n = 12)
Mph 24.10 ± 
1.74
16.19 ± 
1.401,3
18.91 ± 
2.72
14.78 ± 
0.771,3
Mph + BS 26.19 ± 
1.87
17.42 ± 
3.471,3
12.88 ± 
4.271,3
2.58 (one 
mice)
CEP immu-
nized  
(n = 12)
Mph 27.72 ± 
0.661
26.54 ± 
2.212
25.88 ± 
3.18
28.99 ± 
4.692
Mph + BS 29.62 ± 
0.651
26.52 ± 
3.80
22.25 ± 
3.84
10.23 ± 
4.171,4
Note: 1p < 0.05 compared to intact control; 2p < 0.05 compared to tu-
mor-bearing control; 3p < 0.05 compared to data obtained on day 7 in the 
same group; 4р < 0.05 compared to all the previous time points in the 
same group.
When the data are presented in MI, the difference 
between the two groups is even more evident (Fig. 
2). As compared to intact control, the MI of Mph CAT 
in the CEP group was positive over the entire experi­
ment, MI of Mph + BS CAT turned into negative only 
at the last observation point. While in the control 
tumor­bearing group MIs of both Mph and Mph + 
BS activity were negative starting day 14 of tumor 
growth. Depending on the observation time point, 
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MI was equivalent −17.93%... −35.85% in the case 
of direct Mph CAT and −21.43%... −88.36% for Mph + 
BS CAT.
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Fig. 2. MI as compared to intact control of direct (a) and BS de­
pendent (b) Mph CAT in mice bearing Ehrlich solid carcinoma 
(CEP immunized and nonimmunized)
The NK CTA of control and immunized mice 
is depicted in Fig. 3. As one may see, the NK CTA 
of immunized mice did not differ significantly from 
the data of the intact control group throughout 
the entire experiment. While in the control group 
it sharply decreased on day 28 (p < 0.05 compar­
ing with days 7 and 14 of tumor growth) and was 
significantly lower than that in the intact control 
(MI was equal −60.98%) and CEP (MI equal 
−51.92%) groups.
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Fig. 3. CAT of NK in mice bearing Ehrlich solid carcinoma (CEP 
immunized and nonimmunized) and intact ones
The CAT of CTL in the control group of mice did 
not differ significantly (except the day 14) from the 
intact control level (Table 4). Antibody­dependent 
cytotoxic activity (ADCA) was lower than that 
in the intact control group (p < 0.05 on day 21, and 
p < 0.1 on day 28 of the investigation). The MIs 
compared to the intact control group were −31.31%, 
−41.29% and −37.38% on days 14, 21 and 28, cor­
respondingly.
The CTL CTA and ADCA of the immunized mice 
did not differ significantly from the intact control data. 
As compared to the nonimmunized tumor­bearing 
mice, the ADCA was slightly higher — MI fluctuated 
between 10.73 and 30.13% depending on the day 
of tumor growth (p < 0.07 and p < 0.05 on days 7 and 
28, correspondingly).
Table 4. CAT of T-lymphocytes and ADCA in mice bearing Ehrlich solid 
carcinoma (CEP immunized and nonimmunized) and intact onces
Group
CAT  
index, 
%
Day  
of tumor growth
7 14 21 28
Intact 
control 
(n = 8)
CTL 25.61 ± 1.35
ADCA
25.55 ± 5.53
Non-
immu-
nized  
(n = 12)
CTL 
CTA 27.96 ± 1.69 20.50 ± 2.15
1,3 23.48 ± 0.87 23.71 ± 1.37
ADCA
26.19 ± 1.87 17.55 ± 1.083 15.00 ± 0.631,3 16.00 ± 1.901*,3
CEP im-
munized  
(n = 12)
CTL 
CTA 23.63 ± 5.43 22.34 ± 3.68 24.99 ± 0.49 23.57 ± 0.76
ADCA 29.62 ± 0.652* 20.69 ± 5.22 16.61 ± 2.35 20.82 ± 0.332,3
Note: 1p < 0.05 compared to intact control; 1*0.05 < р < 0.1 compared to in-
tact control; 2p < 0.05 compared to tumor-bearing control; 2*0.05 < р < 
0.1 compared to tumor-bearing control; 3p < 0.05 compared to data ob-
tained on day 7 in the same group.
The BS CTA (Fig. 4) of both immunized and non­
immunized mice did not differ significantly from the 
intact control data on the first two time points, but 
sharply increased on days 21 and 28 of the experi­
ment (p < 0.05 in both cases for both groups). The 
difference in BS CTA of immunized and control tumor­
bearing mice was insignificant.
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Fig. 4. BS CAT in mice bearing Ehrlich solid carcinoma (CEP 
immunized and nonimmunized) and intact ones
The mice of both control tumor­bearing and im­
munized groups produced EC­Ag­ and CEP­specific 
Abs (Fig. 5, a and 5, b). The percentage of control mice 
producing Abs specific to ether EC­Ag or CEP was 
almost stable over the experiment (except for sharp 
increase of CEP­specific positive mice on day 14, 
p < 0.05 as compared to days 7 and 21). In the group 
of the treated mice, the pattern was completely differ­
ent. The percentage of EC­Ag or CEP­specific Abs­
positive mice was surprisingly low at day 7: 54.55 and 
50.00%, respectively. Starting on day 14 the percen­
tage of mice expressing Abs specific to EC­Ag or CEP 
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have significantly increased (p < 0.05 as compared 
to day 7 data for both Ags); on days 21 and 28 all the im­
munized mice were positive for both EC­Ag and CEP­
specific Abs (p < 0.05 as compared to day 7 for both 
Ags). Even more, on the last two observation points 
the percentages of Abs­positive mice (for both Ags) 
were significantly higher than that in the control group.
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Fig. 5. Percentage of animals expressing EC­Ag specific (a) and 
CEP­specific (b) Abs in the groups of mice bearing Ehrlich solid 
carcinoma (CEP immunized and nonimmunized ones)
The level of either EC­Ag or CEP­specific Abs 
did not differ significantly over the experiment in the 
control group (Fig. 6, a). It just can be mentioned that 
on days 21 and 28 of the experiment the level of EC­
Ag specific Abs was slightly higher than the level 
of CEP­specific Abs inside the group (p < 0.06 and 
p < 0.07, correspondingly). In the immunized group 
the level of Abs specific to EC­Ag was relatively 
stable over the experiment (except slight increase 
on day 21; p <  0.06 as compared with day­7 data). 
Although the level of CEP­specific Ab was continu­
ously growing (compared to day 7, p < 0.08 on day 14, 
p < 0.05 on days 21 and 28; compared to day 14, 
p < 0.05 on day 28). On days 21 and 28, the level 
of CEP­specific Ab was higher (p < 0.05 and p < 0.07, 
respectively) than that in the control group.
The level of medium size CIC in BS of the control 
tumor­bearing mice was gradually and stably grow­
ing over the experiment (p < 0.07 on day 21 and 
p < 0.05 on day 28 as compared to day 7 level), 
so on day 28 it was significantly higher than that in the 
intact control group (Fig. 7). In the group of immunized 
mice, the CIC level was changing but without signifi­
cant differences as compared to both the intact and 
control tumor­bearing mice.
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Fig. 6. Level of EC­Ag (a) or CEP (b) specific Abs in BS in mice 
bearing Ehrlich solid carcinoma (CEP immunized and nonim­
munized ones)
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Fig. 7. Level of medium size CIC in BS in mice bearing Ehrlich 
solid carcinoma (CEP immunized and nonimmunized) and intact 
ones
DISCUSSION
So, we observed the inhibition of tumor growth 
in the group of immunized mice. The maximal ITGI 
reached 50.57 and 50.74% on days 13 and 16 after 
the tumor challenge (which corresponds to days 5 and 
8 after the last immunization). The mean survival time 
of immunized mice was 25.64% longer (p < 0.05) 
than that of the control mice (58.86 days vs 43.77). 
We considered these effects sufficient to continue 
further investigations.
To unravel mechanisms that underlie the anticancer 
effect of CEP, immunological analysis of the immunized 
and control tumor­bearing mice has been carried out. 
It can be concluded that immunization with CEP did 
not elicit remarkable immune cell activation. On the 
other hand, the immunized mice showed fewer signs 
of immune system exhaustion and tumor­caused sup­
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pression. The protection effect is especially evident 
when it comes to activity of Mph (both cytotoxic and 
cytochemical) and NK.
Even more striking is difference in BS effects 
on immune cells of the treated and the control tumor­
bearing mice. For example, BS of immunized mice 
increased or did not affect CTA of Mph or lymphocytes, 
correspondingly. While in the control group of mice, 
BS led to significant reduction in Mph and lymphocytes 
activities. The CIC increase can be assumed at least 
as one of causes which lead to inhibitory activity of BS, 
as long as CIC are well known as so called “blocking 
factors” and may unfavorably affect the immunity 
of tumor­bearing hosts [19] by modulating cellular 
and humoral immune responses through interaction 
with NK, Mph, B­ and T­lymphocytes [20]. Indeed, 
in the control group correlation between tumor vo­
lume and the level of CIC was positive (r = 0.63, 95% 
CI 0.85–0.22, p < 0.02), whereas correlation between 
CIC level and Mph CTA (both with and without BS) was 
negative: r = −0.71 (95% CI −0.07... −0.93, p < 0.03) 
and r = −0.69 (95% CI −0.08... −0.91, p < 0.03). On the 
other hand, in the group of immunized mice no statisti­
cally significant correlation has been found. So, it looks 
as if immunization with CEP prevented excessive CIC 
generation/accumulation or enforced CIC elimination.
Neither immunized nor control mice elicited anti­
cancer CTL response, but a large percentage of mice 
of both control and treatment groups expressed EC­
Ag and/or CEP­specific Abs. The last fact matches with 
another report that Balb/c mice are prone to Th2 type 
immune response rather than to Th1 [21].
The role of humoral immune response in antican­
cer defense is still debatable, and is often considered 
rather negative than positive [22–27]. Taking this into 
consideration, the correlation analysis between the 
level of ether EC­Ag or CEP­specific Abs and the im­
mune effectors’ CTA was carried out. In the control 
group of mice, there was strong negative correlation 
between the level of EC­Ag specific Abs and NK CAT 
(r = −0.65, 95% CI −0.04... −0.92, p = 0.037) but strong 
positive correlation between EC­Ag specific Abs and 
BS CAT (r = 0.57, 95% CI 0.10–0.93, p = 0.026). In the 
group of immunized mice, the level of EC­Ag specific 
Abs had negative correlation with lymphocytes ADCA 
(r = −0.65, 95% CI −0.94... 0.12, p = 0.046).
In the control group, the level of CEP­specific 
Abs showed strong negative correlation with NK CAT 
(r = −0.66, 95% CI −0.92... −0.05, p = 0.037), lympho­
cyte ADCA (r = −0.78, 95% CI −0.95... −0.3, p = 0.01) 
and BS­dependent Mph CAT (r = −0.63, 95% CI −0.92... 
0.01, p = 0.056). In the treatment group, the concen­
tration of CEP­specific Ab correlated inversely with 
lymphocyte ADCA (r = −0.75, 95% CI −0.08... −0.96, 
p = 0.046) only. What is the reason that almost the same 
concentration of Abs in different groups of mice had 
different relations with immune cells’ activity? It is very 
likely that the mice of the treatment group expressed 
Abs specific to other Ag than that in the control group. 
Both CEP and EC­Ag are rough tissue extracts consist­
ing of a large number of Ag. So, in the ELISA the same 
OD could be generated due to high concentration of Abs 
specific to just one Ag, or due to the summation of low 
concentrations of Abs specific to two or more distinct 
Ags. Other than ELISA techniques (for instance Wes­
tern blotting) would solve this issue. The answer may 
be helpful in the case of CEP­based vaccine purification 
and standardization.
It is very interesting that in the control group the le­
vel of CEP­specific Abs correlated strongly with the le­
vel of EC­Ag specific Abs (r = 0.816, 95% CI 0.56–0.93, 
p = 0.0002), while in the immunized group this rela­
tions is less evident (r = 0.51, 95% CI 0.02–0.8, p = 
0.039). These findings allow us to assume that CEP 
and EC­Ag share some similar epitops or Ags, as long 
as it looks like the presence of CEP­specific Abs in the 
control group is due to the cross­reaction of the EC­
Ag specific Abs. While in the immunized group, factors 
other than just cross­reacting EC­Ag specific Abs af­
fect the induction and the level of CEP­specific Abs.
In conclusion, the tumor­bearing mice of the 
control and immunized groups showed induction 
of humoral immune response. However, in the group 
of immunized mice the response was more balanced: 
contrary to the control mice, autologous BS increased 
or at least did nod suppress CAT of Mph or lympho­
cytes, medium size CIC did not increase significantly, 
and Abs interfere with the only one immune cells’ reac­
tion (to compare, in the control group were three nega­
tive relations). Moreover, the immunization elicited 
moderate activation of cellular immune response and 
preserved its functioning until the late stage of tumor 
growth. All together, these effects led to the tumor 
growth suppression and survival time prolongation. 
The further elaboration of a xenogeneic anticancer 
vaccine based on CEP is warranted.
CONCLUSION
Application of the CEP to Ehrlich solid carcinoma 
bearing mice results in suppressed tumor growth and 
significantly prolonged survival time. Applied under 
the therapeutic scheme, CEP had modulating and 
protecting effects on the immune system of EC bea­
ring mice. The most notable effects are the induction 
of balanced Abs response, the preserving of CAT 
of Mph and lymphocytes, balancing the medium size 
CIC level and converting from negative to positive 
influence of BS on activity of immune cells.
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